Visium Asset Management’s Juno Therapeutics, Inc. JUNO Stock Holding History

Visium Asset Management’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-13,304	Closed	-$710K	–	1314
2015 Q2	$710K	Buy	+13,304	New	+$706K	0.01%	573
2015 Q1	–	Sell	-40,523	Closed	-$2.12M	–	1278
2014 Q4	$2.12M	Buy	+40,523	New	+$1.81M	0.03%	410

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GAMA

Graticule Asia Macro Advisors New York $649M AUM

Visium Asset Management's JUNO Position: Q3 2015 in Review

Visium Asset Management sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 13,304 shares — an estimated $710K sold.

Visium Asset Management first reported a position in JUNO in Q4 2014 and held it in 2 quarters. The position peaked at $2.12M in Q4 2014. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

Visium Asset Management reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Visium Asset Management sold 13,304 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $710K.
Visium Asset Management first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 2 quarters.
Visium Asset Management's Juno Therapeutics, Inc. position peaked at $2.12M in Q4 2014.
132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.